J&J col­lab­o­rates with Aldeyra on new drugs for sys­temic in­flam­ma­to­ry dis­eases

A few months af­ter post­ing mid-stage da­ta sug­gest­ing that its lead drug could be on a path to prov­ing its worth in treat­ing var­i­ous con­di­tions aris­ing from oc­u­lar in­flam­ma­tion, Aldeyra Ther­a­peu­tics $ALDX has scored a col­lab­o­ra­tion pact with the re­search arm at J&J.

The proof-of-con­cept work in dry eye dis­ease and an­te­ri­or uveitis ev­i­dent­ly at­tract­ed the phar­ma to re­prox­alap. Their drug is an alde­hyde se­ques­ter­ing agent, and J&J will now set up a joint steer­ing com­mit­tee to work on more of this cat­e­go­ry of agents.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.